Tesofensine — Safety, Research, Risks & Legal Status

Not medical advice. Tesofensine is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	NS2330, triple monoamine reuptake inhibitor
Category	Research Chemical
phase_stage	Phase 3 (as of 2024-2025)
mechanism_class	triple monoamine reuptake inhibitor
investigational_status	True
weight_loss_phase2_percent	10.2
US legal status	Not FDA-approved. Currently in clinical trials for obesity in Denmark and other jurisdictions. Investigational drug status; not approved for any indication in the USA or most countries.

What is Tesofensine?

A triple monoamine reuptake inhibitor (TMRI) that increases norepinephrine, dopamine, and serotonin levels in the brain. Designed to increase energy expenditure and reduce appetite through central stimulation, distinct from GLP-1 pathway drugs.

How it works

Tesofensine blocks reuptake of norepinephrine, dopamine, and serotonin, increasing synaptic concentrations. Enhances sympathetic tone (thermogenesis, lipolysis) and reduces appetite via serotonergic and dopaminergic pathways, distinct from hormonal mechanisms.

Background & history

Originally developed as antidepressant candidate in late 1990s. Repurposed for obesity in 2010s by Saniona. Phase 2 obesity trials conducted in Denmark starting ~2019; Phase 3 enrollment ongoing.

What the research says

Phase 2 clinical trials report weight loss of 10-12% over 16 weeks in obesity patients (superior to current approved agents in trial arms). Mechanism differs from GLP-1 agonists; works via sympathomimetic and serotonergic pathways. Limited long-term data; Phase 3 trials ongoing in 2024-2025.

Reported effects

Reported weight loss of 10-12% in Phase 2 trials
Reported increased energy expenditure and reduced appetite
Reported mood improvement and increased wakefulness (stimulant-like effects)
Preclinical evidence for reduced food intake via CNS pathways
May increase systemic metabolic rate and thermogenesis
Animal models suggest reduced reward-driven eating

Dosing & administration (informational)

Phase 2 studies used 0.25-0.5 mg daily oral dosing. No approved dose established; Phase 3 will determine final regimen if efficacy and safety confirmed.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Sympathomimetic effects: tachycardia, hypertension, palpitations in early trials
Nausea, dizziness, insomnia reported in Phase 2
CNS stimulant adverse effects: anxiety, tremor possible
Cardiovascular safety not fully characterized in long-term exposure
Reuptake inhibitor mechanism overlaps with antidepressants; drug-interaction risk
Potential for serotonin syndrome if combined with other serotonergic agents

Drug & supplement interactions

Serotonin syndrome risk with SSRIs, SNRIs, MAOIs, tramadol
Sympathomimetic agents: additive cardiovascular effects (dangerous)
Hypertensive crisis risk with decongestants and certain blood-pressure medications
Linezolid and dextromethorphan: serotonin syndrome risk
Cardiac medications: monitor for arrhythmias and QT prolongation

Who should avoid it

Uncontrolled hypertension or cardiac disease
Current SSRI, SNRI, MAOI, or other serotonergic drug use
Narrow-angle glaucoma
Pheochromocytoma
Severe anxiety or bipolar disorder history

How it is commonly combined

Tesofensine should never be combined with other stimulants, serotonergic drugs, or antidepressants due to risk of serotonin syndrome, hypertensive crisis, and cardiovascular complications.

Legal & regulatory. Not FDA-approved. Currently in clinical trials for obesity in Denmark and other jurisdictions. Investigational drug status; not approved for any indication in the USA or most countries.

Quality & harm reduction

A
v
a
i
l
a
b
l
e
o
n
l
y
i
n
c
l
i
n
i
c
a
l
t
r
i
a
l
s
e
t
t
i
n
g
s
;
n
o
c
o
m
m
e
r
c
i
a
l
s
u
p
p
l
y
.
I
f
s
o
u
r
c
e
d
o
u
t
s
i
d
e
t
r
i
a
l
s
(
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
m
a
r
k
e
t
)
,
p
u
r
i
t
y
a
n
d
s
t
e
r
i
l
i
t
y
u
n
v
e
r
i
f
i
e
d
;
h
i
g
h
e
s
t
c
o
n
t
a
m
i
n
a
t
i
o
n
a
n
d
b
a
t
c
h
-
v
a
r
i
a
b
i
l
i
t
y
r
i
s
k
a
m
o
n
g
c
o
m
p
o
u
n
d
s
l
i
s
t
e
d
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

When will tesofensine be approved?

Phase 3 trials are ongoing (2024-2025). No FDA approval timeline announced. May be years away or may not succeed.

How does it differ from GLP-1 drugs?

Tesofensine works via monoamine reuptake inhibition and CNS stimulation; GLP-1 drugs work via peptide-receptor signaling and gastric effects. Different mechanisms, different safety profiles.

Is it safe to use outside trials?

Tesofensine outside clinical trials is investigational and uncontrolled; efficacy and safety data are limited to trial populations, and sourcing is unregulated.

What about cardiovascular risks?

Sympathomimetic effects raise heart rate and blood pressure; long-term cardiovascular safety unknown. Not suitable for patients with hypertension or cardiac history.

Why not just use stimulant medications like phentermine?

Tesofensine has triple monoamine action vs phentermine's primary sympathomimetic effect. Phase 2 weight loss (10-12%) exceeds phentermine efficacy in trials, but long-term safety unknown.

References & further reading

Phase 2 trial data from Saniona obesity program
FDA breakthrough designation documentation
CNS drug development reviews in obesity journals
Ongoing Phase 3 trial registries on ClinicalTrials.gov